A Phase 2, Randomized, Placebo-Controlled, Double-Masked Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRX, an Antisense Inhibitor of Complement Factor B, in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)
Sprache der Bezeichnung:
Deutsch
Original Kurzfassung:
A Phase 2, Randomized, Placebo-Controlled, Double-Masked Study
to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRX,
an Antisense Inhibitor of Complement Factor B, in Patients with
Geographic Atrophy Secondary to Age-Related Macular
Degeneration (AMD)
Forschungs-